HRD + BRCA2 mutation
|
Prostate Cancer
|
HRD + BRCA2 mutation
|
Prostate Cancer
|
olaparib Sensitive: C3 – Early Trials
|
olaparib Sensitive: C3 – Early Trials
|
HRD + BRCA2 mutation
|
Ovarian Cancer
|
HRD + BRCA2 mutation
|
Ovarian Cancer
|
niraparib Sensitive: C3 – Early Trials
|
niraparib Sensitive: C3 – Early Trials
|
HRD + BRCA2 mutation
|
Fallopian Tube Cancer
|
HRD + BRCA2 mutation
|
Fallopian Tube Cancer
|
niraparib Sensitive: C3 – Early Trials
|
niraparib Sensitive: C3 – Early Trials
|
HRD + BRCA2 mutation
|
Peritoneal Cancer
|
HRD + BRCA2 mutation
|
Peritoneal Cancer
|
niraparib Sensitive: C3 – Early Trials
|
niraparib Sensitive: C3 – Early Trials
|